AXP vs STRO · P/E 20, rev $41.30B vs rev $62.0M
American Express Company (AXP) versus Sutro Biopharma (STRO) — a side-by-side from cached financials, not a winner call.
American Express Company (AXP) is a credit services company listed on US.
Sutro Biopharma (STRO) is a biotechnology company listed on NASDAQ.
Latest reported AXP revenue for 2025-12-31 was $41.30B. Net income was $10.83B. Revenue was up 6.4% from 2024-12-31 to 2025-12-31. AXP currently screens at market cap $215.94B and trailing P/E 19.8.
Latest reported STRO revenue for 2024-12-31 was $62.0M. Net income was -$227.5M. Revenue was down 59.6% from 2023-12-31 to 2024-12-31. STRO currently screens at market cap $470.8M.
AXP currently screens at market cap $215.94B and trailing P/E 19.8. STRO currently screens at market cap $470.8M.
Not investment advice. Open the AXP and STRO stock pages for the full models.
Not investment advice.